Navigation Links
Drug for pediatric brain cancer

Scientists from Canada are reporting promising results from a study of a new drug for children with acute brain tumors. The drug fotemustine, when delivered intravenously every three weeks, was found to be partially effective in shrinking the tumors.
//
The drug is one of a group of drugs called chloroethylnitrosoureas. They were first discovered in 1959 and have since been shown to help shrink solid tumors, including cancerous brain tumors. Studies in adults with brain tumors showed fotemustine was at least partially effective in about 20 percent of patients.

In this study, researchers from the Hospital for Sick Children in Toronto tested the drug in 14 children under age 20 with various types of malignant brain tumors, including primary tumors and tumors caused by cancer that had spread to the brain. All of the children had exhausted conventional.

Together the children received a total of 40 doses of the medication. Images were then taken to measure the response to the drug. Three children demonstrated a positive response to the drug, with one showing a 50 percent or greater reduction in the tumor and the other two showing 25% to 50% reductions. The drug was generally well-tolerated by the children.

The researchers believe these results indicate a need for further study of fotemustine for the treatment of pediatric brain tumors and suggest the need for more studies involving the drug alone or possibly in combination with other agents.


'"/>




Page: 1

Related medicine news :

1. Medicis Pharmaceutical company enters pediatric market
2. Drug for pediatric brain cancer
3. Lorenzos oil for prevention of pediatric neurological disorder
4. British pediatricians urge parents to administer MMR to children
5. Multi billion-dollar suit filed against cell phone firm for causing brain tumours
6. Two doctors suspended for wrong brain surgery
7. The brain loves a surprise
8. Increase in sugar...decrease in brain function!!!
9. Alcohol shrinks brain
10. Roller coaster takes brain for a big ride!!
11. The big brain in suicides
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/18/2017)... ... August 18, 2017 , ... “Depressed: Super Heroes of the ... to reflect upon the stories and the relevance these tales may have on the ... Jessica Linhart, a former special education teacher, Jessica spends much of her time enjoying ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... “Steve the ... lesson. “Steve the Snake” is the creation of published author, Harold Flash Haskins Jr., ... and a Department of Defense police officer. , “I write moral-based short stories for ...
(Date:8/17/2017)... ... August 17, 2017 , ... The award-winning producers of ... the National Council for Therapeutic Recreation Certification (NCTRC), slated to air nationwide, fourth ... NCTRC is a non-profit, international organization dedicated to professional excellence for the protection ...
(Date:8/17/2017)... ... August 17, 2017 , ... Georgia Urology, ... Dr. Kristi Hebert to its newest location in East Cobb (4800 ... Dr. Hebert come aboard,” said Dr. Mark A. Haber, Georgia Urology’s managing partner. “She ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... opportunity for IDNs and healthcare systems to interact with their GPO and supplier ... Karla Barber, RN, BCN, CVAHP, System Director of Clinical Value Analytics, have been ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... , August 17, 2017 DarioHealth ... Company with mobile health and big data solutions, ... agreements with domestic and non-U.S. investors for the ... and shares of the Company,s newly designated Series ... offerings. The Company expects to conduct a closing ...
(Date:8/15/2017)... N.C. , Aug. 15, 2017 AccuGenomics, ... NC , today announced that the company has ... the University of North Carolina at Chapel Hill and ... is designed to characterize and quantify HIV reservoir and ... after pharmacological intervention. The HIV Cure Center is a ...
(Date:8/8/2017)... 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical ... financial results for the second quarter ended June 30, ... quarter 2017 and to date: ... for the Company,s lead project, BL-8040: ... BL-8040 as novel stem cell mobilization treatment for autologous ...
Breaking Medicine Technology: